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Background: In osteosarcoma (OS) and most Ewing sarcoma (EWS) patients, the primary tumor originates in the
bone. Although tumor resection surgery is commonly used to treat these diseases, it frequently leaves massive
bone defects that are particularly difficult to be treated. Due to the therapeutic potential of mesenchymal stem
cells (MSCs), OS and EWS patients could benefit from an autologous MSCs-based bone reconstruction. However,
safety concerns regarding the in vitro expansion of bone marrow-derived MSCs have been raised. To investigate the
possible oncogenic potential of MSCs from OS or EWS patients (MSC-SAR) after expansion, this study focused on a
biosafety assessment of MSC-SAR obtained after short- and long-term cultivation compared with MSCs from healthy
donors (MSC-CTRL).
Methods: We initially characterized the morphology, immunophenotype, and differentiation multipotency of
isolated MSC-SAR. MSC-SAR and MSC-CTRL were subsequently expanded under identical culture conditions. Cells
at the early (P3/P4) and late (P10) passages were collected for the in vitro analyses including: sequencing of genes
frequently mutated in OS and EWS, evaluation of telomerase activity, assessment of the gene expression profile and
activity of major cancer pathways, cytogenetic analysis on synchronous MSCs, and molecular karyotyping using a
comparative genomic hybridization (CGH) array.
Results: MSC-SAR displayed comparable morphology, immunophenotype, proliferation rate, differentiation
potential, and telomerase activity to MSC-CTRL. Both cell types displayed signs of senescence in the late stages of
culture with no relevant changes in cancer gene expression. However, cytogenetic analysis detected chromosomal
anomalies in the early and late stages of MSC-SAR and MSC-CTRL after culture.
Conclusions: Our results demonstrated that the in vitro expansion of MSCs does not influence or favor malignant
transformation since MSC-SAR were not more prone than MSC-CTRL to deleterious changes during culture.
However, the presence of chromosomal aberrations supports rigorous phenotypic, functional and genetic
evaluation of the biosafety of MSCs, which is important for clinical applications.
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Bone sarcomas, a heterogeneous group of rare malignant
tumors of mesenchymal origin [1], occur primarily in
adolescents and young adults. Bone sarcomas are classi-
fied genetically into two categories: osteosarcoma (OS) is
characterized by complex karyotypes indicative of severe
genetic and chromosomal instability [2], while Ewing’s
sarcoma (EWS) is characterized by the presence of
tumor-specific translocations. OS is the most common
primary tumor of the bone and it is usually found at the
end of long bones, often around the knee [3]. The eti-
ology of OS is not well understood, as well as a clear link
between OS and inherited genetic mutations or specific
genetic changes has not been established, although pa-
tients with Li-Fraumeni syndrome have a high risk of
developing OS by inheriting mutations that silence the
p53 tumor suppressor gene (for a comprehensive review
see [4]). EWS typically develops in the femur and tibia.
The most common mutation associated with EWS
involves a translocation of chromosomes 22 and 11
(t (11;22)), which fuses a portion of the EWSR1 gene with
a portion of the FLI1 gene to create a EWS/FLI-1 fusion.
This is a non-inheritable somatic mutation acquired only
in tumor cells during a person’s lifetime [5,6].
Despite considerable improvements in the diagnosis
and treatment of OS and EWS, progress in patient sur-
vival has remained stagnant for more than two decades
[7-9]. Current OS and EWS treatments consist of mul-
tiple modalities, traditionally including amputation or
limb-sparing surgery, with the goal of complete tumor
removal. Adjuvant therapies—such as radiation and
chemotherapy—are used selectively in an effort to
minimize both local recurrence and distant metastasis of
the disease. Tumor resection often causes a massive bone
defect that is difficult to treat. Thus, OS and EWS patients
could benefit from a mesenchymal stem cell (MSC)-based
therapeutic approach to bone reconstruction, alone or
in combination with biomaterials to provide a structural
support.
Recognition of the regenerative potential of MSCs is
one of the most exciting fields in cell-based therapy;
their safety and efficacy has been reported in > 250 clin-
ical trials [10]. MSCs are appealing because they can be
isolated easily from bone marrow (BM) and several other
human tissues, can be expanded in vitro, have a high
proliferative capacity, lack immunogenicity, display im-
munomodulatory properties, retain the ability to secrete
soluble factors that regulate crucial biological functions,
such as proliferation and differentiation over a broad
spectrum of target cells [11], and target damaged tissues
and tumor sites (for a review see [12,13]). Most import-
antly, the ability of MSCs to differentiate into several
cell lineages makes them ideal for reparative medicine
[14-16].The use of MSCs for clinical applications requires
in vitro expansion. However, there is concern about the
chromosomal stability and biosafety of expanded human
MSCs, particularly those derived from sarcoma patients
(for updated reviews see [17,18]). Several studies have
indicated that murine MSCs acquire chromosomal ab-
normalities after a few in vitro passages and generate OS
after the in vivo transplantation [19,20]. In contrast,
MSCs derived from healthy human donors or patients
with Crohn’s disease do not undergo malignant trans-
formation after the in vitro expansion [21-26]. Centeno
et al. [27,28] reported that 227 patients treated for vari-
ous orthopedic conditions by implanting autologous
MSCs that had been expanded in vitro using growth fac-
tors supplied by a platelet lysate did not experience any
evident neoplastic complication with > 2 years of follow-
up. Thus, it remains to be determined whether MSCs
derived from healthy or sarcoma affected-patients have
functional defects that could hamper therapeutic effi-
cacy. In this study, we evaluated the characteristics of
BM-derived MSCs from sarcoma patients and healthy
controls in vitro to assess their oncogenic potential be-
fore clinical application.
Methods
Study design
The in vitro biosafety profiles of BM-derived MSCs from
OS and EWS patients (MSC-SAR) were compared to those
of BM-MSCs from control healthy donors (MSC-CTRL)
after expansion under the same culture conditions. Poten-
tial hallmarks of tumorigenic transformation were assessed
by characterizing MSC morphology and immunopheno-
type, osteogenic and adipogenic differentiation, sequencing
genes frequently mutated in OS and EWS, evaluating
telomerase activity, assessing the gene expression profile of
major cancer pathways, as well as cytogenetic analysis on
synchronous MSCs, and molecular karyotyping using a
comparative genomic hybridization (CGH) array.
Patients
The study was approved by the Rizzoli Orthopedic Insti-
tute Ethics Committee (Bologna, Italy), and all patients
provided informed consent. Seven bone sarcoma pa-
tients and six healthy donors were included. Detailed in-
formation about the bone sarcoma patients is shown in
Table 1.
Isolation of bone marrow nucleated cells and MSCs
expansion
Isolation of BM-derived MSCs was performed as de-
scribed previously [29] through gradient separation and
plastic adherence. Briefly, 8 mL of undiluted BM aspirate
were loaded into a BD Vacutainer® CPT™ tube (Becton
Dickinson, Franklin Lakes, NJ, USA) and then processed
Table 1 Characteristics of patients and bone sarcomas
Sample ID Gender Age Diagnosis Location
MSC-SAR 1 F 36 Osteosarcoma Proximal humerus
MSC-SAR 2 M 45 Osteosarcoma Distal femour
MSC-SAR 3 M 17 Ewing Sarcoma Iliac crest
MSC-SAR 4 M 20 Osteosarcoma Distal femour
MSC-SAR 5 M 12 Ewing Sarcoma Femour
MSC-SAR 6 M 63 Condrosarcoma Acetabolar
MSC-SAR 7 M 17 Osteosarcoma Femour
F, female; M, male.
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layer containing plasma and mononuclear cells was har-
vested. The cell number was counted and the viability
evaluated. For expansion, cells were then transferred
to 150-cm2 culture flasks by seeding 4 × 105 cells/cm2
with α-Modified Minimum Essential medium (α-MEM;
BioWhittaker, Lonza, Verviers, Belgium) supplemented
with 20% lot-selected fetal bovine serum (FBS; Gibco,
Invitrogen-Life Technologies, Paisley, UK) and 1% Glu-
taMAX™ (Invitrogen-Life Technologies). The flasks were
incubated at 37°C in a humidified atmosphere of 5%
CO2 with medium change every 3–4 days. When the
cells reached ~70–80% confluence, they were detached
by mild trypsinization (TripLe™ Select, Invitrogen-Life
Technologies) for 3 min at 37°C and counted. Cells were
reseeded into a new 150-cm2 flask at a density of 4000
cells/cm2.
Immunophenotypic characterization
Phenotypic characterization of MSCs was performed by
fluorescence-activated cell sorting (FACS) analysis of
cell-surface markers at passage 2 (P2). MSCs were la-
beled with monoclonal antibodies against CD34, CD45,
CD44, CD90, CD105, CD166 (Beckman Coulter, Fuller-
ton, CA, USA) and CD146 (Miltenyi Biotech, Bergisch
Gladbach, Germany). Control samples were labeled with
isotype-matched control antibodies (Beckman Coulter,
Brea, CA, USA). In brief, cells were trypsinized and ali-
quoted at a concentration of 1 × 106 cells/mL, fixed in
0.5% formalin for 20 min, and washed once in PBS.
Next, samples were incubated with either conjugated
specific antibodies or isotype-matched control mouse
immunoglobulin G at the recommended concentrations.
Labeled cells were washed twice and suspended in FACS
buffer. The analysis was performed using a FC500 flow
cytometer (Beckman Coulter).
Cell proliferation
Cell number and viability were assessed for each passage
using a NucleoCounter® device (ChemoMetec, Lillerød,
Denmark) that detects non-viable cells by propidium
iodide nuclear staining and determines cell viability bycalculating the ratio of non-viable to total cell numbers.
The number of population doublings (PD) for each pas-
sage was calculated using the formula: log2(N1/N0),
where N0 is the number of cells seeded and N1 the num-
ber of cells harvested at the end of the passage and cu-
mulative population doubling (CPD) refers to the sum of
PDs over passages.Senescence assay
Senescence was detected by staining MSCs with a β-
galactosidase (SA-β-gal) staining kit (Cell Signaling
Technologies, Danvers, MA, USA) according to the
manufacturer’s instructions, and analyzed with a direct-
light microscope. Briefly, 1 × 104 cells were plated in a
35-mm2 dish and incubated overnight at 37°C. After re-
moving the growth medium, cells were washed twice with
PBS, fixed for 10–15 min at room temperature, and incu-
bated at 37°C overnight in a dry incubator (atmospheric
CO2) with fresh β-gal staining solution. β-gal–positive
cells were monitored under a microscope for the develop-
ment of blue color and subsequently imaged.MSCs differentiation in vitro
Osteogenic differentiation was induced at P3 by seeding
MSCs in α-MEM supplemented with 2% FBS in six-well
plates at 5 × 105 cells per well. The next day, an osteogenic-
inducing cocktail composed of 10 mM β-glycerophosphate
(Sigma, St. Louis, MO, USA), 50 μg/mL ascorbic acid
(Sigma) and 100 nM dexamethasone (Sigma) was added.
As a negative control, cells seeded under the same condi-
tions were maintained in a non-inducing medium. Media
were changed twice per week. After 14 days, the samples
were stained with Alizarin Red-S (AR-S) (Sigma) to reveal
the deposition of a calcium-rich mineralized matrix [30].
Adipogenic differentiation was induced at P3 by seeding
5 × 105 MSCs/well in a six-well plate in Dulbecco’s
Modified Essential Medium-high glucose (DMEM–HG;
Euroclone, Milan, Italy) supplemented with 2% FBS (Gibco)
and incubated overnight to allow cell attachment. Then,
medium was switched to adipogenic-induction medium
composed of DMEM–HG supplemented with 2% FBS,
10 μM bovine insulin (Sigma, St Louis, MO, USA), 1 μM
dexamethasone (Sigma), 200 μM indomethacin (Sigma)
and 500 μM 3-isobutyl-1-methyl xanthine (IBMX, Sigma).
As a negative control, cells seeded under the same condi-
tions were maintained in non-inducing medium. Media
were changed twice per week. After 21 days, the presence
of lipid depots was visualized by staining samples with Oil
Red O. In brief, cells were washed twice with phosphate-
buffered saline (PBS; Euroclone, Milan, Italy), fixed in 4%
paraformaldehyde (Sigma) for 10 min and stained with
0.18% Oil Red O (Sigma) for 15 min.
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It has been reported [21] that 20–25 valuable metaphase
cells/slides can be obtained by synchronizing MSCs. To
synchronize the cell cycle, MSCs at > 80% confluence
were detached, re-plated at 7000 cells/cm2, and main-
tained in culture medium without FBS for 20 h. After
that, complete medium containing FBS was returned to
the cultures for 27–28 h and incubated at 37°C with
0.1 mM colcemid solution (Irvine Scientific, Santa Ana,
CA, USA). After 4 h, cells were harvested, treated with
0.56 mM KCl, and fixed in methanol/acetic acid (3:1).
Cells in metaphase were Q-banded and karyotyped in
accordance with the International System for Human
Cytogenetic Nomenclature recommendations.
CGH array
Molecular karyotyping was performed by CGH array with
the Agilent kit 2 × 105 K (Human Genome CGH Micro-
array, v. 5.0, Agilent Technologies, Santa Clara, CA, USA),
according to the manufacturer’s protocol, as described pre-
viously [24]. The analysis was performed on four MSC-SAR
and four MSC-CTRL samples. The minimum positive cri-
teria for an imbalance was considered to be three consecu-
tive oligomeres with a log2 ratio different from zero; thus,
the theoretical resolution of the 105 K 60-mer oligonucleo-
tide platform was ~80 kb. DNA was extracted using
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Array-CGH ex-
periments were analyzed using the Agilent scanner and
Feature Extraction software (v. 9.1). A graphical overview
was obtained using the CGH Analytics software (v. 3.4.27).
Quality control parameters for each experiment were evalu-
ated using the QC metric tool in the CGH Analytics
software.
Telomerase activity assay
Telomerase activity was measured by a quantitative real-
time PCR-based telomeric repeat amplification protocol
(TRAP). MSC-SAR and MSC-CTRL were analyzed by
the TeloExpress quantitative telomerase detection kit
(Express Biotech International, Thurmont, USA), ac-
cording to the manufacturer’s instructions. The Huh7
cell line was used as a telomerase-positive control. The
results obtained from each MSC sample were compared
with a control template standard curve for final absolute
quantification of telomerase activity, expressed as atto-
mole of telomerase repeat sequences in 1-μg protein
(attomol/μg protein).
Gene sequencing
MSCs obtained from cultures of sarcoma and healthy do-
nors were harvested at early and late passages and washed
in PBS buffer. DNA was isolated using the Nucleospin
Blood kit (Macherey-Nagel, Dueren, Germany) accordingto manufacturer’s instructions. DNA quality and quantity
were assessed with a NanoQuant Infinite M200 instru-
ment (Tecan Group Ltd, Männedorf, Switzerland) before
sequencing.
DNA samples were analyzed for mutational screening of
TP53, CDKN1A/p21 and MDM2 genes. The 11 exons of
TP53, the 3 exons of CDKN1A along with exon–intron
junctions, and SNP309 (rs2279744) in MDM2 were PCR-
amplified using primer sequences that will be available
upon request. The amplification products were purified
using ExoSap-IT reagent (USB Corp., Cleveland, OH, USA)
and sequenced in both the forward and reverse directions
using BigDye Terminator chemistry version 3.1 (Applied
Biosystems, Foster City, CA, USA). Purification of sequen-
cing products was performed with BigDye X-Terminator
kit and samples were analyzed using an ABI Prism 3100
automated DNA sequence (Applied Biosystems). Refer-
ence sequences for TP53, CDKN1A, and MDM2 were ob-
tained from GenBank (accession numbers NM_000546.4,
NM_000389 and NM_002392.3, respectively).
Gene expression analysis
Total RNA from MSC-SAR and MSC-CTRL harvested
at early and late culture passages, as well as from sub-
confluent osteosarcoma cell line U2OS (#HTB-96, ATCC,
Teddington, United Kingdom), was isolated using the
Qiagen RNeasy mini kit (Qiagen) according to the manu-
facturer’s instructions. RNA concentration was assessed
with a NanoQuant Infinite M200 instrument (Tecan Group
Ltd, Männedorf, Switzerland) and RNA integrity was veri-
fied spectrophotometrically by 260/280 nm ratios > 2.0 and
260/230 nm ratios > 1.7. An equal amount of RNA (500 ng)
was used for reverse transcription using the RT2 First
Strand Kit (Qiagen) using protocol steps that eliminated
genomic DNA.
qPCR experiments were performed using the Human
Cancer Pathway Finder PCR Array (RT2 Profiler PCR
Array PAHS-033R, SABioscience, Frederick, MD, USA)
and RT2 SYBR Green ROX Fast Mastermix (Qiagen) on
a Rotor-Gene Q instrument. The total volume of the
PCR reaction was 20 μL and reactions were setup with a
Biomek® NX Span-8 automated workstation (Beckman
Coulter, Indianapolis, IN, USA) equipped with an
adaptor designed to hold Rotor-disc 100 (Qiagen). The
thermocycler parameters were 95°C for 10 min, followed
by 40 cycles at 95°C for 15 s and then at 60°C for 30 s.
The PCR array profiles the expression of 84 genes in-
volved in transformation and tumorigenesis. Four house-
keeping genes (B2M, HPRT1, RPL13A, ACTB), RT
controls, and PCR controls were included in each run.
Relative expression of target genes was determined
using the ΔΔCq method, as described by Livak and
Schmittgen [31]. PCR-array data were analyzed using the
web-based software “RT2 Profiler PCR Array Data Analysis
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analysis was performed on four MSC-CTRL, four MSC-
SAR, and three U2OS samples.
Statistical analysis
Linear regression of CPD curves from MSC-SAR (n = 6)
and MSC-CTRL (n = 6) was performed using GraphPad
Prism version 5.00 for Windows (GraphPad Software,
San Diego, California USA). The same software was used
to compare the mean best-fit slope of two groups.
Results
Characterization of MSCs
To characterize MSCs isolated from the BM of sarcoma
patients and controls, we evaluated cell morphology,Figure 1 Morphological analysis and in vitro differentiation of mesen
(MSC-SAR) patients. (A) The morphology of MSC-CTRL and MSC-SAR sam
MSC-CTRL and MSC-SAR at early (P3) and late (P10) passages. White boxes
bar = 100 μm. (B) Osteogenic differentiation assay of MSC-CTRL and MSC-S
of non-induced MSC-CTRL and MSC-SAR, and after 14 days in osteogenic m
matrix by differentiated MSCs. Scale bar = 100 μm. (C) Adipogenic different
bright-field images of Oil Red O staining of non-induced MSC-CTRL and M
indicates fat deposits, a hallmark of fully differentiated adipocytes. Scale baexpression of typical surface markers and differenti-
ation potential into mesodermal lineage cells. Both
populations displayed the typical spindle-shaped ap-
pearance at early passages and exhibited a smoothened
morphology after long-term expansion, developing a
larger and more granular cytoplasm (Figure 1A). FACS
analysis documented that > 80% of the MSC-CTRL
and MSC-SAR expressed the typical MSC markers
CD44, CD90, CD105, CD146, CD166, whereas the
expression of the hematopoietic markers CD45 and
CD34 was <10%. No quantitative differences were
observed (data not shown). Furthermore, MSC-CTRL
and MSC-SAR displayed the expected osteogenic
(Figure 1B) and adipogenic differentiation potentials
(Figure 1C).chymal stem cells from control (MSC-CTRL) and sarcoma
ples with culture passage. Representative bright-field images of
indicate areas of magnification shown in the lateral panels. Scale
AR samples. Representative bright-field images of Alizarin Red staining
edium. Red staining highlights deposition of mineralized extracellular
iation assay of MSC-CTRL and MSC-SAR samples. Representative
SC-SAR and after 21-day culture in adipogenic medium. Red staining
r = 50 μm.
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We measured the proliferation rate of six MSC-CTRL
and six MSC-SAR samples using standard growth curve
analysis during 30 days in culture, which corresponded
to seven passages. Despite the considerable variability
in proliferation kinetics, cumulative population doubling
(CPD) analysis revealed that the MSC-SAR proliferation
rate from P3 to P10 was comparable to MSC-CTRL
(Figure 2). Moreover, both MSC-CTRL and MSC-SAR,
entered a senescent phase within 100 days (P7) of cul-
ture, as shown by β-gal staining (Figure 3). This was sup-
ported by the observation that a larger number of β-gal
positive cells were observed at late (P10, Figure 3B) than
at early (P4, Figure 3A) passages.MSC-SAR and MSC-CTRL exhibit chromosomal aberrations
The genetic stability of the in vitro expanded MSC-
CTRL and MSC-SAR was evaluated after the in vitro
expansion by both molecular and conventional karyo-
typing. CGH array analysis did not demonstrate any
chromosomal abnormalities or sub-microscopic rear-
rangements (data not shown). However, CGH arrays
cannot detect balanced chromosomal rearrangements, a
problem which can be avoided by simultaneously per-
forming a conventional cytogenetic analysis. In this
case, conventional karyotyping did not detect macro-
scopic chromosomal rearrangement but did detect
tetraploid cells in both early and late passages of MSC-
SAR, as well as in MSC-CTRL cultures (Figure 4). Ana-
lysis of 211 metaphase cells obtained from five MSC-SAR
lots detected 46 tetraploid cells (22%), while 8 tetraploid
cells (18%) were detected within the 45 metaphase cellsFigure 2 Proliferation of mesenchymal stem cells from control
(MSC-CTRL) and sarcoma (MSC-SAR) patients during in vitro
expansion. Cumulative population doubling (CPD) from MSC-CTRL
(n = 6) and MSC-SAR (n = 6) during seven passages. Results are
expressed as best-fit linear regression lines (solid lines) with 95% <
confidence intervals (dashed lines).obtained from two MSC-CTRL lots. We could not iden-
tify chromosomal aberrations frequently associated with
bone tissue tumors, such as monosomy 13 [33].MSC-SAR have low levels of telomerase activity
To evaluate telomerase activity, we determined the abil-
ity of telomerase to synthesize telomeric repeats onto
an oligonucleotide substrate in vitro upon the addition
of deoxynucleotides (dNTPs). Extended products were
subsequently amplified by PCR. Five MSC-CTRL and
five MSC-SAR at early (P4) and late (P10) passages were
tested. All MSC samples showed a passage-associated
decrease of telomerase activity (Figure 5). The mean value
in MSC-SAR was 4.96 × 10−5 ± 1.87 × 10−5 attomol/μg pro-
tein at P4 (range 3.6–8.5 × 10−5 attomol/μg protein) and
4 × 10−5 ± 1.94 × 10−5 attomol/μg protein at P10 (range
1.21–6.17 × 10−5 attomol/μg protein). The mean telomerase
activity in MSC-CTRL cells was 3.48 × 10−5 ± 1.98 × 10−5
attomol/μg protein at P4 (range 3–7.2 × 10−5 attomol/μg
protein) and 1.62 × 10−5 ± 2 × 10−5 attomol/μg protein at
P10 (range 0.9–3.04 × 10−5 attomol/μg protein).MSC-SAR do not have specific DNA sequence alterations
Direct sequencing of all exonic and intronic boundaries
of TP53 and CDKN1A, along with MDM2 SNP309, was
performed in order to evaluate sequence variations in
DNA samples from MSC-CTRL and MSC-SAR har-
vested at early and late passages (see Table 2 for de-
tails). Deficiencies in TP53 and CDKN1A, the primary
regulators of cell cycle progression and apoptosis nor-
mally involved in protection against tumorigenesis, can
be the origin of some mesodermic tumors [34,35].
Since MDM2 encodes an important negative regulator
of the p53 protein, we also assessed the status of
MDM2 SNP309 (rs2279744), which is located in the
MDM2 promoter. All donors analyzed showed the
presence of exonic and/or intronic polymorphisms in
TP53 (Table 2). All of these variants were reported in
the TP53 database as benign sequence variations [36].
CDKN1A sequencing revealed only one sequence vari-
ant in MSC-SAR 4 (rs1059234), which had been de-
scribed previously [37], and is not associated with
cancer [38]. The heterozygous presence of SNP309
(rs2279744 T > G) in MDM2 was detected in three do-
nors (Table 2). No pathological mutations were found
in the analyzed genes. Notably, all TP53, CDKN1A, and
MDM2 variants identified in each donor were detected
in all DNA samples analyzed. Moreover, the hetero- or
homozygous status of these variations did not change
at different culture time points. In addition, to detect
the presence of the EWS/FLI-1 fusion transcript, we
performed RT-PCR amplification using primers span-
ning the EWS/FLI-1 fusion region [39] on MSC-SAR
Figure 3 Senescence assay. Evaluation of β-galactosidase activity in MSC-SAR at passage (A) 4 (P4) and (B) 10 (P10). Senescent cells are stained
blue. Scale bar = 100 μm.
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5). Interestingly, we did not detect EWS/FLI-1 expres-
sion in either sample (data not shown).
Gene expression in cancer pathways was not significantly
altered in MSC-SAR
To identify a possible variation in markers correlated
previously to tumorigenesis and determine whether
these markers were specifically associated to bone sar-
coma etiology, we investigated gene expression levels in
MSC-CTRL and MSC-SAR samples at different passages
after the in vitro culture (see Table 3 for details). The
analysis was performed using the RT2 Profiler PCR
Array by SABioscience, which is designed to characterize
84 genes representative of biological pathways involved
in transformation and tumorigenesis, cell cycle control
and DNA damage repair, apoptosis and cell senescence,
signal transduction molecules and transcription factors,Figure 4 Karyotype analysis. Q-banding karyotype of representative MSC
System for Human Cytogenetic Nomenclature recommendations.adhesion, angiogenesis, invasion and metastasis. Results
from this analysis are shown in table form (Additional
file 1: Table S1) and graphically (Figure 6). Altered gene
expression was defined as up- or down-regulation ≥ 2-
fold and a p value ≤ 0.05. The expression of 15 genes
(7 genes at P3 and 11 at P10) was significantly different
in MSC-SAR than in MSC-CTRL. Over- or under-
expression of these genes are presented as fold regu-
lation in Table 3, along with corresponding results
obtained by comparing osteosarcoma cells from the ref-
erence tumor cell line U2OS with MSC-CTRL. At P3,
MMP9 and TNF were overexpressed genes in MSC-SAR
(Figure 6A and Table 3). However, at late passages no
differences in gene expression were observed. We did
observe that increased expression of ANGPT2 and
CDC25A was maintained throughout culture passages
(Figure 6A,B); however, these genes are not correlated
with bone sarcoma etiology.-SAR tetraploid cells analyzed in accordance with the International
Figure 5 Telomerase activity. Telomerase activity of five MSC-SAR
and five MSC-CTRL samples at P4 and P10, as detected by TRAP
assay. Results are expressed as means ± standard deviation (n = 5).
Table 2 p53, CDKN1A and MDM2 sequence analysis
Donor ID
(passages analyzed)
TP53
refSNP Exon Status
MSC-SAR 1 (p4/p10)
rs1642785 2 HO
rs17878362 3 HO
rs1042522 4 HO
MSC-SAR 2 (p4/p10)
rs1642785 2 HE
rs17878362 3 HO
rs1042522 4 HE
MSC-SAR 3 (p4/p6)
rs1642785 2 HO
rs17878362 3 HO
rs1042522 4 HO
MSC-SAR 4 (p4/p10)
rs1642785 2 HE
rs17878362 3 HE
rs1800370 4 HE
rs1042522 4 HE
MSC-SAR 5 (p4/p10)
rs1642785 2 HE
rs17878362 3 HO
rs1042522 4 HE
rs12947788 7 HE
rs12951053 7 HE
MSC-SAR 6 (p4/p10)
rs17878362 3 HO
rs12947788 7 HE
rs12951053 7 HE
MSC-CTRL 1 (p4/p10)
rs1642785 2 HO
rs17878362 3 HO
rs1042522 4 HO
MSC-CTRL 2 (p3/p10)
rs1642785 2 HO
rs17878362 3 HO
rs1042522 4 HO
Sequence analysis of DNA samples from MSC-SAR and MSC-CTRL patients was perf
the 11 exons of TP53, the 3 exons of CDKN1A along with exon–intron junctions, and
HE, heterozygous.
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derived growth factor B (PDFGB), which is involved in
the regulation of proliferation in cells of mesenchymal
origin, increases over time during culture in MSC-SAR
(Figure 6B). Moreover, expression of the tumor suppres-
sor gene SERPINB5 was higher in MSC-SAR than in
MSC-CTRL at late culture passages (Figure 6B). Con-
versely, vascular endothelial growth factor A (VEGFA)
gene was slightly underexpressed in MSC-SAR at early
stages of culture (Figure 6A) and decreased with time in
culture (Figure 6B).
As expected when we compared U2OS with MSC-
CTRL, we found a higher number of genes with greater
levels of dysregulation. Of the 84 genes evaluated, we de-
tected 33 that were altered (Figure 6C, Additional file 1:
Table S1). U2OS cells strongly overexpressed MMP9CDKN1A p21 MDM2 SNP 309
refSNP Exon Status refSNP Status
rs2279745 HE
rs1059234 3 HE
rs2279745 HE
rs2279745 HE
ormed at the indicated culture passages. PCR amplification was performed on
on the SNP309 (rs2279744) in MDM2. P, passages; HO, homozygous;
Table 3 Gene expression analysis of cancer pathways
MSC-SAR vs MSC-
CTRL P03
MSC-SAR vs MSC-
CTRL P10
U2OS vs MSC-CTRL
P03
GENE
SYMBOL
Refseq Description Fold
Regulation
T-TEST
p value
Fold
Regulation
T-TEST
p value
Fold
Regulation
T-TEST
p value
ANGPT2 NM_001147 Angiopoietin 2 3,60 0,017031 3,54 0,001587 2,01 0,123058
BRCA1 NM_007294 Breast cancer 1, early onset 1,56 0,184634 2,59 0,005080 13,19 0,000088
CDC25A NM_001789 Cell division cycle 25 homolog A (S. pombe) 2,01 0,030181 2,44 0,011524 15,56 0,000083
CFLAR NM_003879 CASP8 and FADD-like apoptosis regulator −3,43 0,013343 −1,91 0,017928 −1,42 0,115505
CHEK2 NM_007194 CHK2 checkpoint homolog (S. pombe) 1,03 0,930306 1,23 0,735103 7,49 0,000340
COL18A1 NM_030582 Collagen, type XVIII, alpha 1 −2,85 0,034861 −1,14 0,967097 2,94 0,018415
E2F1 NM_005225 E2F transcription factor 1 1,69 0,152813 2,64 0,036988 18,50 0,000019
GZMA NM_006144 Granzyme A (granzyme 1, cytotoxic T-
lymphocyte-associated serine esterase 3)
4,14 0,064832 3,86 0,021397 2,28 0,018937
IFNA1 NM_024013 Interferon, alpha 1 2,15 0,231676 4,32 0,000719 −4,17 0,208829
IGF1 NM_000618 Insulin-like growth factor 1 (somatomedin C) 3,98 0,023798 5,26 0,003415 1,41 0,704213
MMP9 NM_004994 Matrix metallopeptidase 9 (gelatinase B, 92 kDa
gelatinase, 92 kDa type IV collagenase)
4,05 0,033049 2,76 0,957572 152,53 0,000000
PDGFB NM_002608 Platelet-derived growth factor beta polypeptide 2,41 0,057864 2,80 0,027891 174,40 0,000107
SERPINB5 NM_002639 Serpin peptidase inhibitor, clade B (ovalbumin),
member 5
4,32 0,056954 3,54 0,010117 4,04 0,000712
TNF NM_000594 Tumor necrosis factor 4,04 0,030749 2,77 0,010705 1,54 0,285973
VEGFA NM_003376 Vascular endothelial growth factor A −1,97 0,006089 −6,84 0,008108 −12,44 0,000009
Genes differentially expressed in MSC-SAR compared to MSC-CTRL at early and late passages characterized in the Human Cancer Pathway Finder PCR Array (RT2
Profiler PCR Array PAHS-033R, SABioscience), and analyzed using the provided RT2 Profiler PCR Array Data Analysis v. 3.5 software [32]. Results of the same genes
analyzed in U2OS cells are reported for comparison. Bold characters indicate genes up- or down-regulated by ≥ 2-fold and with a p-value ≤ 0.05. The analysis was
performed on four MSC-CTRL, four MSC-SAR samples and three independent samples of sub-confluent U2OS cells.
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tential of this cell line coupled with high expression
levels of genes involved in cell cycle regulation (i.e.,
BRCA1, CCNE1, CDC25A, CHEK2, E2F1), apoptosis
(i.e., BCL2, BCL2L1), membrane integrity and tumor in-
vasion (i.e., COL18A1, ITGA3, MMP9, MCAM), cell pro-
liferation (i.e.,. PDFGA, PDGFB), and tumor suppression
(i.e., SERPINB5). Among the underexpressed genes, p16
(CDKN2A) exhibited the greatest downregulation (145-
fold decrease), which confirmed that the loss of p16
expression is correlated with osteosarcoma development
[40]. Moreover, we confirmed reports in the literature
describing over-expression of PDGFB [41].
Discussion
The most common surgical techniques used to treat
osteosarcoma around the knee include resection of
the epiphysis and reconstruction with a prosthesis, an
osteoarticular allograft, an autoclaved autograft, or a
combination of the above. The functional results of
prostheses and osteoarticular grafts are not satisfactory
because of limited durability, joint instability, incongru-
ity, and gross distortion of the normal anatomy. It has
been reported that autologous MSCs loaded onto hy-
droxyapatite scaffolds can successfully heal segmentalbone defects in human and animal models [42-44]. In
human bone diseases, MSCs are usually delivered or
applied locally, often in combination with suitable
scaffolds, when it is necessary to provide mechanical
stabilization or support to osteosynthesized fractures of
long bones [45] and in atrophic non-unions. Although
controversial, MSCs seeded on hydroxyapatite scaffolds
have also been used to heal defects derived from curet-
tage of a bone tumor as an alternative to autologous
bone grafting [46]. However, the possible risks of MCSs
transplantation are debated. Major concerns have been
raised with regard to the biosafety of the in vitro ex-
panded MSCs, particularly when intended for autolo-
gous transplantation in a cell therapy protocol for bone
reconstruction of sarcoma patients. Data from a mouse
xenograft model proposed that MSCs are precursors
of tumor stromal cells [47] or might differentiate into
tumor-associated fibroblast-like cells when cultured in
tumor cell-conditioned supernatant [48]. Therefore, our
in vitro studies will facilitate the safe use of expanded
autologous MSCs for tissue engineering strategies to
induce bone reformation.
In the present work, we performed cell expansion ex-
periments under previously standardized culture condi-
tions [29] and assessed in vitro the biosafety profile of
Figure 6 Gene expression analysis of cancer pathways. Gene
expression analysis was performed using the RT2 Profiler PCR Array
PAHS-033R SABioscience. Volcano plots of MSC-SAR samples (n = 4)
compared to MSC-CTRL (n = 4) at early (A) and late (B) passages are
reported. The volcano plot of the U2OS tumor cells versus
MSC-CTRL samples is shown in (C). Also see Table 3.
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pared to control donors. Based on the “hallmarks of
cancer” criterion [49], human cells acquire biological
capabilities during tumor development in a multi-step
process. These hallmarks include sustaining proliferativesignaling, evading growth suppressors and enabling rep-
licative immortality, which are all traits found in OS cell
lines. We investigated the hallmarks of cancer in MSC-
SAR at several levels; the results suggest that MSC-SAR
exhibit comparable morphology, immunophenotype, pro-
liferation rate, differentiation potential, and telomerase
activity to MSCs of healthy donors. The in vitro expan-
sion of both MSC-SAR and MSC-CTRL resulted in a
progressive aging mechanism coupled to typical traits of
altered cell morphology that are consistent with a previ-
ous study [50].
DNA sequencing of TP53, CDKN1A/p21 and MDM2,
which are key players in cell cycle regulation and are
involved in tumor of mesenchymal origin, did not detect
pathological mutations. In addition, the existence of tetra-
ploid cells in both early and late passages of MSCs cultures
raises the crucial question whether MSCs clones with a
genomic imbalance may acquire a malignant phenotype
in vivo, although they are able to reach the senescence
phase in vitro. The detection of tetraploid cells at similar
percentages from MSC-SAR and MSC-CTRL suggests that
this chromosomal aberration is not a distinctive feature of
MSCs expanded in vitro from the BM of sarcoma patients.
Rather, this chromosomal aberration may be induced by
in vitro culture conditions during expansion procedures
that are optimized to achieve a high proliferation rate and
to obtain the large number of cells necessary for the ana-
lyses and for cell-based therapy approaches. Moreover, it is
worth considering that polyploidies were already present in
early culture passages, but these positive clones did not
acquire a proliferative advantage during culture. These data
are in agreement with a previous report by Tarte et al. [51]
documenting, by conventional karyotype analysis, donor-
dependent chromosomal abnormalities in healthy donor
BM-MSCs that did not confer a selective advantage to the
affected clone.
Gene expression analysis of 84 genes involved in cancer
development provided a comparison of MSC-SAR and
MSC-CTRL at a translational level. In this study, we used
U2OS as a reference tumor cell line and, as expected, 33 of
84 genes investigated were altered when compared to
MSC-CTRL. Interestingly, we observed down-regulation of
p16 expression, which is responsible for escape from senes-
cence and restoration of cell proliferation activity. Further-
more, several genes were overexpressed > 100-fold in U2OS
compared to MSC-CTRL. As an example, MMP9 was
overexpressed 152-fold, which is pertinent since MMPs are
involved primarily in the breakdown of extracellular matrix
and possibly promotion of tumor invasion.
A comparison of gene expression between MSC-SAR
and MSC-CTRL revealed that the expression of 15 genes
was significantly different, although none of these genes
are principally involved in bone sarcoma etiology. While
the expression of these 15 genes was altered in U2OS
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MSC-SAR and MSC-CTRL. For example, MMP9 was in-
creased 4.05-fold in MSC-SAR compared to MSC-CTRL
at P3, even though no significant difference in MMP9 ex-
pression was found at P10, suggesting that an increase in
MMP9 expression in MSC-SAR was not a stable indicator.
ANGPT2 and CDC25A maintain higher expression levels
during in vitro culture in MSC-SAR compared to MSC-
CTRL, but expression of these genes has not been cor-
related with bone sarcoma etiology (Figure 6A,B). Our
analysis determined that expression of the mitogenic
growth factor PDFGB increased with time in culture in
MSC-SAR (Figure 6B). Moreover, the level of the tumor
suppressor gene SERPINB5 was higher in MSC-SAR at late
culture passages (Figure 6B). Conversely, VEGFA was
slightly underexpressed in MSC-SAR at early stages of cul-
ture (Figure 6A), and decreased over time (Figure 6B).
Gene expression analysis could provide a signature that
will facilitate routine evaluation of the safety of in vitro-
expanded MSCs and assessment of the presence of suspi-
cious modifications. Our results support the hypothesis that
MSC-SAR do not present a greater risk of undergoing
transformation compared to MSC-CTRL. More extensive
analysis should be performed to confirm the dysregulation
of cancer pathways and exclude possible effects resulting
from MSCs aging. The expression of tumor suppressor
genes and oncogenes may in fact shift with time in culture
and be influenced by stress response mechanisms that are
activated under in vitro culture conditions. Our encour-
aging in vitro results will be expanded upon using in vivo
approaches to confirm MSC-SAR safety in an animal model
through long-term follow-up and careful examination of
the transplanted animals.
Conclusions
In conclusion, our findings suggest that BM-MSC derived
from OS or EWS patients that are expanded in vitro are
not prone to malignant transformation during culture.
Nevertheless, the considerable percentage of cells displaying
a chromosomal abnormality strongly indicates the necessity
for genomic monitoring and rigorous evaluation of the bio-
safety profiles of the lots prepared for cell therapy. Conse-
quently, the risks must be weighed carefully against the
potential benefits to the patient.
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Finder PCR Array (RT2 Profiler PCR Array PAHS-033R, SABioscience), and
analyzed using the provided RT2 Profiler PCR Array Data Analysis v. 3.5
software [32]. Bold characters indicate genes up- or down-regulated
by≥ 2-fold and with a p-value ≤ 0.05. The analysis was performed on four
MSC-CTRL, four MSC-SAR samples and three independent samples of
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